Clinical Trials Logo

Locally Advanced Paraganglioma clinical trials

View clinical trials related to Locally Advanced Paraganglioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04106843 Withdrawn - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Start date: June 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Radioactive drugs, such as 177Lu-DOTATATE, may carry radiation directly to cancer cells and not harm normal cells. 177Lu-DOTATATE may help to control endocrine cancers compared to standard treatment.

NCT ID: NCT02302833 Active, not recruiting - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Start date: February 17, 2015
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.